ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.
ViaNautis has raised $24.6M in total funding. The most recent round was Series A. The last funding was announced in November 2023.
ViaNautis's investors include Eli Lilly, 4BIO Capital, Abcam, Cystic Fibrosis Foundation, BGF Ventures.
ViaNautis is headquartered in Cambridge, United Kingdom.
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.
ViaNautis is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ViaNautis — Funding & Investors." VCBacked, November 13, 2023, https://www.vcbacked.co/company/vianautis. Accessed July 30, 2026.
VCBacked. (2023). ViaNautis — Funding & Investors. Retrieved July 30, 2026, from https://www.vcbacked.co/company/vianautis
{{cite web |title=ViaNautis — Funding & Investors |url=https://www.vcbacked.co/company/vianautis |website=VCBacked |access-date=July 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated